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Background: A population-based case control study was performed to determine the 
associations of Pro12Ala polymorphism in peroxisome proliferator-activated receptor-γ (PPARG) 
and Gly308Ala polymorphism in tumor necrosis factor-α (TNFA) genes in obese subjects.
Patients and methods: Of 1,400 eligible subjects, 20 years, we recruited only 1,127. For 
extreme phenotype case-control design, we evaluated 201 subjects with body mass index (BMI) 
30 kg/m2 (Group 1) and 143 with BMI ,20 kg/m2 (Group 2). Clinical, anthropometric, bio-
chemical, and nutritional details and polymorphisms were estimated.
Results: In Group 1, the dietary intake of calories and fats was higher, physical activity was 
lower, and prevalence of truncal obesity, hypertension, high total cholesterol, low high-density 
lipoprotein cholesterol, and diabetes was greater than in Group 2. There were no homozygous 
polymorphisms of either gene. Heterozygous Pro12Ala polymorphism in PPARG was found in 
15 (7.5%) subjects in Group 1 and 3 (2.1%) subjects in Group 2 (P = 0.028), and heterozygous 
Gly308Ala polymorphism in TNFA was found in 19 (9.5%) in Group 1 and 7 (4.9%) in Group 2 
(P = 0.115). Presence of heterozygous polymorphism in PPARG and TNFA-predicted obesity 
with univariate odds ratio ([OR], 95% confidence intervals) of 2.25 (1.32–3.84, P = 0.003) and 
1.48 (1.10–1.99, P = 0.009) and with multivariate OR 1.74 (1.03–2.93, P = 0.038) and 1.46 
(1.05–2.03, P = 0.024), respectively. The addition of dietary and physical activity variables did 
not result in significant change.
Conclusion: Obese Asian Indians have greater prevalence of heterozygous polymorphisms of 
Pro12Ala in PPARG and Gly308Ala in TNFA genes.
Keywords: obesity, Asian Indian, Pro12Ala polymorphism, diet, urban
Introduction
Obesity is emerging as a major public health problem in low income countries including 
India.1,2 Early in the 20th century, most populations in which obesity became a public 
health problem were in North America and Europe. Recent data show that the largest 
increases in obesity are in developing countries, such as Mexico, China, and Thai-
land.3,4 Global estimates using both longitudinal and cross-sectional data indicate 
that the prevalence of obesity in countries in intermediate development has increased 
by 30%–100% over the past decade.3 Serial studies in India have shown a significant 
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that the prevalence has almost doubled in the last 20 years.4–6 
Significant prevalence of obesity has also been reported 
from industrial populations,7 urban slums,8 and among rural 
populations9 in India.
There are multiple factors associated with the increase in 
obesity in developing countries, perhaps the most important 
being urbanization and globalization of food production 
and marketing that result in an obesogenic environment.1,3,10 
  Obesity has a strong genetic component as well.11 These 
genetic differences account for 30%–50% of the variation 
in fatness in a population.3 Multiple chromosomal locations, 
genes, and genetic polymorphisms have been implicated.11 
Although whole-genome analysis techniques have provided 
important information about chromosomal locations, linkages, 
and polymorphisms (eg, fat mass and obesity-associated [FTO] 
gene),12 the study of single-nucleotide associations (SNPs) are 
important for identification of pathophysiological pathways.13 
Limited research has been done on associations of SNPs with 
obesity in Asian Indians and none has been conclusive.14–18
We performed a population-based epidemiological study 
in an urban location in India to identify the prevalence 
of obesity.19,20 The study used an extreme phenotype 
case-control design and compared the prevalence of Pro12Ala 
polymorphism in peroxisome proliferator-activated receptor-γ 
(PPARG) and Gly308Ala polymorphism in tumor necrosis 
factor-α (TNFA) genes in obese (body mass index [BMI] 
30 kg/m2) and thin (BMI  20 kg/m2) persons. These 
two SNPs were chosen because outside the relationship of 
FTO gene, these two have the most robust evidence for 
obesity.11 Secondly, in India, obesity (especially truncal 
obesity) is significantly associated with impaired glucose 
tolerance and diabetes, and both of these genes have been 
identified as important in pathobiological pathways that lead 
to insulin resistance and inflammation in obese subjects. 
Significant association of these SNPs has previously been 
reported with type 2 diabetes, insulin resistance, and cen-
tral obesity.11,14–18,21,22 The extreme phenotypic approach 
used in this study has been previously evaluated in genetic 
epidemiological studies and is an important method when 
the absolute number of subjects is small.23,24
Methods
A population-based genetic epidemiological study was 
performed in an ethnically homogenous group.19 Subjects 
belonging to a community that hailed from Punjab region in 
north India were studied. House-to-house survey was con-
ducted to identify obese subjects in this population group and 
for this the whole population of Punjabi subjects living in that 
location was screened. In a previous study, among a similar 
community at Jaipur, we reported the prevalence of obesity 
(BMI 30 kg/m2) of about 25%.20 We, therefore, targeted a 
sample size of 1,400 subjects, expecting a response rate of 
70%, so that more than 200 obese subjects could be recruited 
for the genetic epidemiological study.20 The study was 
approved by the institutional ethics committee, and informed 
consent was obtained from all the participants.
Data collection
A detailed proforma was utilized for data collection. 
Briefly, we collected information regarding demographic 
data, past history of major illnesses such as coronary heart 
disease, hypertension, diabetes or high cholesterol levels, 
and smoking or tobacco intake and alcohol intake.25 As the 
focus of this case-control genetic epidemiological study 
was subjects with high BMI (Group 1, 30 kg/m2) and low 
BMI (Group 2, ,20 kg/m2) in this subgroup of subjects 
with high and low BMI we performed a detailed dietary 
evaluation using a validated food frequency questionnaire 
and a single 24-hour recall.26 Data from the food frequency 
questionnaire were used to identify calorie intake and intake 
of various macronutrients. Physical activity was inquired 
using a previously validated instrument.27 Physical examina-
tion was performed to assess height, weight, waist and hip 
circumference, and blood pressure (BP) using previously 
reported methodology.25 Body fat percent and visceral fat 
were analyzed using a Karada Fat-Scan machine (Omron 
Model No. HBF-362; Omron Healthcare Singapore Pte 
Ltd, Alexandra Technopark, Singapore) using bioelectric 
impedance method with this hand-held device. The inputs in 
the formula are electric resistance, height, weight, age, and 
gender. Fasting blood sample for glucose and lipid estimation 
(after overnight fast) was obtained from all the subjects with 
very low and high BMI. Fasting glucose was determined at 
a central laboratory using glucose-peroxidase method and 
external quality control. Quality control measures were also 
followed for estimation of total cholesterol, high-density 
lipoprotein (HDL) cholesterol, and triglycerides.28 Low-
density lipoprotein (LDL) cholesterol was estimated using 
the Friedewald formula.
Diagnostic criteria
The risk factors were classified using standard guidelines.25,29,30 
Truncal obesity was defined by waist-to-hip ratio (WHR) 
of .0.95 for men and .0.85 for women.20,25 Smokers 
included subjects with present or past smoking or any 
tobacco use. Hypertension was diagnosed when the   systolic Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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or   diastolic BP was 140/90 mm Hg on a repeated 
single-day measurements or when the individual was a known 
hypertensive. Dyslipidemia was defined by the presence of 
high total cholesterol ($200 mg/dL), high LDL cholesterol 
($130 mg/dL), low HDL cholesterol (, 40 mg/dL), or high 
triglycerides ($150 mg/dL) according to National Choles-
terol Education Program Adult Treatment Panel-III (ATP-III) 
guidelines.30 Diabetes was diagnosed when a subject provided 
history of previously diagnosed diabetes or the fasting blood 
glucose was 126 mg/dL.
genetic analyses
Blood sample was collected for genetic analyses in groups 
with high and low BMI.24 EDTA-anticoagulated venous 
blood samples were collected from all study subjects, and 
the genomic DNA was isolated from whole blood by pro-
teinase K digestion followed by ethanol precipitation. DNA 
was isolated locally and stored at −70°C. Detection of the 
polymorphisms was carried out using amplification and 
restriction enzyme digestion technique. SNPs of possible 
importance in obesity were tabulated (Table 1) and because 
of financial reasons, we evaluated polymorphisms only in 
PPARG gene important in adipogenesis and TNFA gene 
important in inflammatory pathways. In the PPARG gene, we 
studied the Pro12Ala polymorphisms, and in TNFA gene, the 
Gly318Ala polymorphism was studied. All the SNP analyses 
were performed at a national laboratory using previously 
described methodologies.31 The Pro12Ala polymorphism 
in PPARG gene was genotyped using the upstream primer 
5′–GCC AAT TCA AGC CCA GTC-3′ and the downstream 
primer 5′–GAT ATG TTT GCA GAC AGT GTA TCA GTG 
AAG GAA TCG CTT TCC G-3′. The polymerase chain 
reaction (PCR) product was digested overnight using the 
enzyme BStU1. The Gly318Ala polymorphism in TNFA 
gene was genotyped using upstream primer 5′–AGG CAA 
TAG GTT TTG AGG GCC AT-3′ and downstream primer 
5′–GAG CGT CTG CTG GCT GGG TG-3′. The amplified 
product was digested overnight using the restriction enzyme 
NCo1. The digested PCR products were resolved on 2%–3% 
agarose gel stained with ethidium bromide. Details including 
Table 1 candidate genes and single nucleotide polymorphisms associated with obesity according to biological pathways
Central 
neuronal 
signaling 
pathway
Adipogenesis Energy  
metabolism  
and  
thermogenesis
Leptin- 
insulin  
signaling 
pathway
Inflammatory 
cytokines
Hormone 
signaling  
pathway
Renin- 
angiotensin  
pathway
Undetermined 
pathways
AgrP AcDc AcP1 ABcc8 iL6 Ar Ace FTO
cArT ADPn DA BTc iL6r ccKAr AgT –
DrD2 APM1 ADrA2B gcgr iL10 crhr1 hSD11B1 –
DrD4 APOA1 ADrB2 iDe LTA cYP11B2 – –
ghrL APOA2 ADrB3 igF2 SerPine1 cYP19A1 – –
gPr24 APOA4 ATP1A2 inS TnF eSr1 – –
hTr1B APOB cAPn10 irS1 – eSr2 – –
hTr2A APOD enPP1 irS2 – ghrhr – –
hTr2c APOe FABP1 LeP – MAOA – –
iDe cBFA2T1 FABP2 LePr – MAOB – –
Mc3r FOXc2 FABP4 PTPrF – MeD12 – –
Mc4r gnB3 FASn reTn – nrOB2 – –
Mc5r inSig2 gAD2 TBc1D1 – ncOA3 – –
nPr3 LDLr gYS1 TcF1 – Pgr – –
nPY LiPc hSPA1B – – SgK – –
nPY2r LiPe PPrgc1A – – SLc6A3 – –
nr3c1 LMnA PTPn1 – – SLc6A14 – –
POMc LPL TUB – – VDr – –
PYY MAcS2 UcP1 – – – – –
Th PLin UcP2 – – – – –
UBL5 POn1 UcP3 – – – – –
Y2r PPArA – – – – – –
– PPArD – – – – – –
– PPArg – – – – – –
– SAh – – – – – –
– ScArB1 – – – – – –
– SOrBS1 – – – – – –
– SreBF1 – – – – – –Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3
Table 2 Demographic details, lifestyle variables, and cardiovascular 
risk factors in the study subjects
Group 1 
BMI $30 kg/m2 
N = 201
Group 2 
BMI ,20 kg/m2 
N = 143
Men:women 82:119 (40.8%)a 81:62 (56.6%)
Age (y) 48.1 ± 12.9a 39.5 ± 17.7
Dietary variables
calories (per d) 2157 ± 383a 1637 ± 204
Fat (g/d) 93.4 ± 18.8a 51.0 ± 8.3
Fat energy (%) 39.0 ± 4.0a 28.4 ± 5.4
SFA energy (%) 23.6 ± 8.1a 13.7 ± 5.8
MUFA energy (%) 9.4 ± 3.1 9.4 ± 2.2
PUFA energy (%) 5.9 ± 3.3b 5.2 ± 1.4
Proteins (g/d) 64.9 ± 18.1a 53.1 ± 10.1
Physical activity variables
energy expenditure (kcal) 1870 ± 142a 2127 ± 417
PALS 1.41 ± 0.12a 1.50 ± 0.13
risk factors
BMi (kg/m2) 34.1 ± 3.8a 18.6 ± 1.2
Waist (cm) 102.9 ± 8.1a 65.0 ± 7.0
Whr 0.92 ± 0.07a 0.80 ± 0.08
hypertension (%) 143 (71.1)a 67 (46.8)
Systolic BP (mm hg) 132.6 ± 15.8a 124.5 ± 14.6
Diabetes (%) 60 (29.8)a 18 (12.6)
glucose fasting (mg/dL) 116.9 ± 5.3a 95.6 ± 40.8
cholesterol (mg/dL) 204.7 ± 52.0 194.6 ± 39.3
hDL cholesterol (mg/dL) 42.6 ± 6.0 43.1 ± 6.3
Triglycerides (mg/dL) 172.8 ± 70.6 158.9 ± 70.5
Significance level: aP , 0.01; bP , 0.05.
Note: numbers in parentheses are percent. Statistical t-test for continuous variables 
and chi-square test for ordinal variables.
Abbreviations:  BMi,  body  mass  index;  SFA,  saturated  fatty  acid;  MUFA, 
monounsaturated  fatty  acid;  PUFA,  polyunsaturated  fatty  acid;  PALS,  physical 
activity level score; Whr, waist-to-hip ratio; BP, blood pressure; hDL, high-density 
lipoprotein.
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location of SNPs in the respective genes, primer sequences, 
PCR conditions, and restriction enzymes with product sizes 
have been reported earlier.31
Statistical analyses
The numerical variables are reported as mean ± 1 SD, and 
ordinal variables are reported in percent. Significance of inter-
group differences was determined using unpaired t-test for 
numerical variables and χ2 test for ordinal variables. Hardy–
Weinberg equilibrium was tested for each of the SNPs based 
on the genotyping of 440 chromosomes from normal healthy 
individuals (average age 35.1 ± 9 years). These were recruited 
on a random basis from different locations, including public 
meeting places, offices, colleges, markets, and hospitals, and 
represented population-based controls as reported earlier.32 
Pearson’s χ2 test (3 × 2 contingency table) was used to assess 
association of SNPs with obesity using the cases (Group 1) and 
controls (Group 2). Allelic and genotypic associations of SNPs 
found significant by the χ2 test were evaluated by computing 
odds ratio (OR) and 95% confidence interval (CI). χ2 values 
were derived from a series of 2 × 2 contingency tables based 
on the frequency of each haplotype vs all others between the 
two groups. Logistic regression analysis was carried out to 
correlate various clinical parameters with genotypes and to 
study pair wise interactions between SNPs of different genes. 
P values were subject to Bonferroni’s correction and considered 
significant when ,0.05.
Results
The overall response rate in the population study was 80.5%, 
and 1,127 (men 556, women 571) of 1,400-invited subjects 
participated in the study. There was a significant prevalence 
of cardiovascular risk factors in the overall study subjects.19 
In men and women, respectively, smoking or tobacco use was 
in 347 (62.4%) and 12 (2.2%), obesity (BMI  25 kg/m2) 
in 303 (54.5%) and 350 (61.3%), truncal obesity with high 
WHR in 339 (61.0%) and 310 (54.30%), and hypertension 
in 322 (57.9%) and 279 (48.9%). Blood biochemistry results 
for fasting glucose and lipids were available for 644 subjects 
(57.1%). High total cholesterol was in 111 (32.6%) men and 
120 (39.5%) women, low HDL cholesterol in 103 (30.3%) 
and 83 (27.3%), high triglycerides in 146 (42.9%) and 132 
(43.4%), metabolic syndrome in 166 (48.8%) and 137 (45.1%), 
and diabetes in 88 (25.9%) and 64 (21.1%), respectively. For 
the present study, subjects were divided into two groups, 
respectively. Subjects with BMI  30 kg/m2 were categorized 
into Group 1 (n = 201) and those with BMI  20 kg/m2 as 
Group 2 (n = 143). There were more women in Group 1 
(119, 59.2%) compared with Group 2 (62, 43.4%; P = 0.004; 
Table 2). In Groups 1 vs Group 2, the dietary intake of calo-
ries, fat energy percent (en%),   saturated fat en%, and proteins 
was significantly greater. Physical activity measured using 
physical activity level score (PALS) was greater in Group 2 
than in Group 1. In Group 1 vs Group 2, the prevalence (%) 
of truncal obesity (49.8 vs 19.6, P , 0.001), hypertension 
(71.1 vs 46.8, P , 0.001), high total cholesterol 200 mg/dL 
(29.9 vs 18.2, P = 0.006), low HDL cholesterol ,40 mg/dL 
(28.9 vs 23.1, P = 0.031), and diabetes (29.9 vs 12.6, P = 0.001) 
was significantly greater.
There was no patient with homozygosity in the PPARG or 
TNFA SNPs in the study Groups (Table 3). The alleles were in 
Hardy–Weinberg equilibrium. Heterozygous Pro12Ala poly-
morphism (AB allele) in PPARG was in 15 (7.5%) subjects in 
Group 1 and 3 (2.1%) in Group 2 (P = 0.028), and heterozy-
gous Gly308Ala polymorphism (AB allele) in TNFA was in Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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19 (9.5%) in Group 1 and 7 (4.9%) in Group 2 (P = 0.115). 
Presence of heterozygous polymorphism of PPARG and 
TNFA genes significantly predicted obesity with univari-
ate OR (95% CIs) of 2.25 (1.32–3.84, P = 0.003) and 1.48 
(1.10–1.99, P = 0.009), respectively. These ORs remained 
significant after multivariate adjustments for age, gender, and 
comorbidities at 1.74 (1.03–2.93, P = 0.038) for AB allele 
in PPARG and 1.46 (1.05–2.03, P = 0.024) for AB allele in 
TNFA. Addition of dietary and physical activity variables 
did not result in significant change, suggesting negligible 
gene-diet or gene-physical activity interactions.
To study the gene-environment interactions, we classified 
lifestyle variables according to the genetic heterozygosity 
(Table 4). It was observed that subjects with PPARG AB allele 
were less physically active and had greater intake of calories 
and fats. These subjects also had significantly greater BMI, 
waist size, and WHR. The mean systolic BP and the preva-
lence of hypertension were not significantly different among 
all the three allelic groups. Fasting blood glucose level was 
  significantly greater in those with PPARG heterozygosity, and 
the   prevalence of diabetes was significantly greater in these 
subjects. Cholesterol and triglyceride levels also were signifi-
cantly greater in these subjects. Subjects with TNFA heterozy-
gosity with AB allele or having heterozygous alleles in both the 
SNPs were also less physically active, consumed more calories 
and fats, and although BMI and waist size were greater, there 
was no difference in WHR. The prevalence of hypertension, 
diabetes and mean lipid levels was not significantly different 
in groups with either TNFA or both polymorphisms.
Discussion
This is the first study to show that obese Asian Indians 
residing in north India have significant polymorphisms 
of heterozygous AB alleles in Pro12Ala in PPARG and 
in Gly308Ala in TNFA genes. This significance remains 
after adjustment for comorbidities and dietary and lifestyle 
variables, suggesting direct pathophysiological influence of 
these genes. Study of gene–environment interactions shows 
Table 3 Distribution of PPArg and TnFA allele polymorphisms in obese and thin subjects
PPARG Pro12Ala polymorphisms TNFA Gly308Ala polymorphisms
AA allele BB allele AB allele P value  
(χ2 test)
AA allele BB allele AB allele P value 
(χ2 test)
Obese (BMi $ 30 kg/m2); n = 201 0 0 15 0.028 0 0 19 0.115
Thin (BMi , 20 kg/m2); n = 143 0 0 3 0 0 7
Abbreviations: PPArg, peroxisome proliferator-activated receptor-γ; TnFA, tumor necrosis factor-α.
Table 4 Lifestyle and phenotypic characteristics of study subjects (n = 344) with and without the presence of PPArg and TnFA 
polymorphisms
PPARG TNFA Both PPARG and TNFA
Present  
(n = 18)
Absent  
(n = 326)
Present  
(n = 26)
Absent  
(n = 318)
Present  
(n = 7)
Absent  
(n = 337)
Men:women 9:9 (50.0) 154:172 (47.2) 11:15 (42.3) 152:166 (47.8) 3:4 (42.8) 160:177 (47.5)
PALS 1.48 ± 0.13a 1.56 ± 1.15 1.50 ± 0.18 1.56 ± 1.17 1.47 ± 0.11 1.55 ± 1.10
calorie intake/d 2472 ± 667a 1911 ± 372 2232 ± 526a 1917 ± 391 2581 ± 712a 1927 ± 393
Fat en%/d 40.0 ± 7.5a 34.3 ± 6.9 34.6 ± 8.7 34.5 ± 6.9 40.3 ± 6.4b 34.5 ± 7.0
SFA en%/d 25.5 ± 9.7a 19.2 ± 8.5 21.8 ± 10.4 19.3 ± 8.5 25.5 ± 8.5 19.4 ± 8.7
BMi (kg/m2) 38.0 ± 10.5a 27.1 ± 7.7 33.3 ± 11.1a 27.2 ± 7.8 34.0 ± 10.4a 26.9 ± 7.6
Waist (cm) 108.1 ± 20.6a 86.0 ± 19.5 95.0 ± 24.6b 86.5 ± 19.7 98.4 ± 22.9a 85.8 ± 19.4
Whr 1.01 ± 0.25a 0.88 ± 0.14 0.98 ± 0.23a 0.88 ± 0.13 0.90 ± 0.10 0.87 ± 0.9
hypertension 9 (50.0) 201 (61.6) 15 (57.7) 195 (61.3) 21 (47.7) 189 (63.0)
Systolic BP (mm hg) 128.6 ± 15.9 129.3 ± 15.8 127.9 ± 13.4 129.4 ± 16.0 128.8 ± 13.8 129.3 ± 16.0
Diabetes 18 (100.0)a 60 (18.4) 11 (42.3)b 67 (21.1) 22 (50.0)a 56 (18.7)
glucose fasting (mg/dL) 235.0 ± 65.4a 99.9 ± 35.9 142.8 ± 72.9a 105.5 ± 47.1 155.8 ± 97.9a 82.7 ± 50.1
cholesterol (mg/dL) 220.4 ± 40.9 199.6 ± 47.9 209.5 ± 41.4 200.0 ± 48.2 188.3 ± 66.3 157.4 ± 77.2
hDL cholesterol (mg/dL) 40.8 ± 5.8 42.9 ± 6.1 42.3 ± 5.2 42.8 ± 6.2 38.4 ± 13.1 35.3 ± 17.5
Triglycerides (mg/dL) 223.1 ± 69.5a 164.0 ± 69.5 187.4 ± 72.8 165.7 ± 70.4 168.5 ± 78.5a 125.5 ± 75.9
Significance level: aP , 0.01; bP , 0.05.
Note: numbers in parentheses are percent. Statistical t-test for continuous variables and chi-square test for ordinal variables.
Abbreviations: PPArg, peroxisome proliferator-activated receptor-γ; TnFA, tumor necrosis factor-α; PALS, physical activity level score; SFA, SFA, saturated fatty acid; 
BMi, body mass index; Whr, waist-to-hip ratio; BP, blood pressure; hDL, high-density lipoprotein.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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that those with PPARG or TNFA polymorphisms consumed 
more calories and fats, and subjects with PPARG had greater 
prevalence of diabetes and lipid levels were more. But larger 
studies are required to confirm these observations.
Over the past two decades, serious efforts were made 
to unravel genes and genetic markers that predispose to 
common obesity.11 The initial epidemiological approaches 
have been limited to candidate gene and linkage studies. 
These approaches have led to the identification of a large 
number of potential candidate genes and quantitative trait 
loci, but very few have been confirmed convincingly.11 The 
candidate gene approach is hypothesis-driven and relies on 
current understanding of the biology and pathophysiology of 
obesity and related traits. The hypothesis is based on the data 
derived from animal models, cellular systems, and extreme 
or monogenic forms of obesity.3 Genetic variants at these 
loci are then tested in population level association studies. 
The number of genetic association studies has grown expo-
nentially over the past 15 years. The latest update of human 
obesity gene map reports 127 candidate genes associated 
with obesity related traits.11,33 Of these, 12 genes (ADIPOQ, 
ADRB2, ADRB3, GNB3, HTR2C, NR3C1, LEP, LEPR, 
PPARG, UCP1, UCP2, and UCP3) have been replicated in 
10 or more studies.21 However, the major problem that has 
plagued the candidate gene approach is that many of these 
studies are small (including less than 1,000 individuals) 
and, thus, often are underpowered.12 With a small sample 
size, positive results do not prove and negative results do 
not disprove a true association.24,34 This is a limitation of the 
present study also because we studied only 343 subjects. 
However, this study used an extreme phenotypic case-control 
design (very high BMI vs very low BMI), and the significant 
presence of heterozygous polymorphisms suggests possible 
importance of these genes. However, as there were no subjects 
with homozygous polymorphisms and the absolute number of 
AB polymorphisms in cases and controls was small, we sug-
gest studies with larger sample sizes to validate these results. 
These observations, however, are also in consonance with 
earlier studies.11 Another issue in genetic epidemiological 
studies is genetic heterogeneity, eg, the FTO gene identified 
recently using genome-wide association studies35 appears 
important mainly in Caucasians and among non-Caucasian 
populations variable results have been reported.36,37
Several groups have reported loss-of-function mutations 
in the ligand-binding domain of human PPARG, specifically 
in the adipose-specific PPARG-2.21,23 Inherited lipodystrophic 
syndromes caused by PPARG mutations are characterized by 
altered distribution of subcutaneous fat, insulin   resistance, 
diabetes, elevated triglycerides, low HDL cholesterol, 
  hypertension, and polycystic ovarian syndrome, but are rare. 
The most common PPARG genetic variant is a polymorphism 
replacing alanine with proline at codon 12 (Pro12Ala) in exon 
B, which encodes part of the PPARG transactivation domain.38 
This variant has an heterozygous allele frequency of 4% in 
Japanese and can reach up to 28% in white cohorts. Low 
overall frequency (5.2%) is observed in the present cohort 
that is consistent with other Asian studies. Multiple gene–gene 
interactions of PPARG have been reported and increased risk 
of obesity and diabetes reported for SNPs in APM1g11391A 
locus, beta-3 adrenergic receptor, interleukin-6, acyl coenzyme 
A synthetase, and adiponectin gene loci.38 In the present study, 
no interaction was observed with TNFA polymorphism, but 
because of the small study size and as we did not study the 
other polymorphisms, we cannot comment on this issue. 
Gene-environment interactions have also been reported for 
PPARG with dietary factors and physical activity. The effect 
of Pro12Ala variant was more apparent in patients with low 
physical activity, and the effects of polyunsaturated:saturated 
fat ratio were additive.38 In this smaller study, we observed that 
those with PPARG were less physically active and consumed 
more calories and fats. Whether PPARG polymorphisms influ-
ence physical activity or appetite through known or unknown 
mechanisms needs more studies. Greater prevalence of dia-
betes in those with the presence of homozygous Pro12Ala 
polymorphisms in PPARG gene and higher total cholesterol 
and triglyceride levels confirms the well known influence of 
PPARG in glucose and lipid metabolism38 and is similar to 
earlier studies.11,18,22,38–40 In the present study, we found only 
heterozygous Pro12Ala polymorphisms and therefore the 
results are not comparable with other studies.
TNFA is expressed in adipocytes, and the elevated levels 
of this cytokine have been linked to obesity and insulin resis-
tance.21 Several population-based studies among Caucasian 
subjects have reported association of Gly380Ala SNP in TNFA 
gene and obesity but some have reported no association.41–44 
On one hand, Brand et al41 studied 176 German Caucasian 
subjects for this polymorphism and reported a significant 
association of this polymorphism with high BMI levels 
(P = 0.013). These findings were replicated in some more 
studies.42,43 On the other hand, Corbolan et al44 failed to report 
a significant association of this polymorphism with BMI in 
Spanish Caucasians subjects (n = 313). Similarly, some stud-
ies reported a positive association of this polymorphism with 
waist size and WHR, whereas others failed to confirm this 
association.11 This study has greater sample sizes than most of 
above-mentioned studies, and there is a significant association. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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Larger studies are needed to confirm these observations as there 
is a physiological role of TNFA system in obesity and related 
metabolic complications.45
Obesity is an important emerging issue in developing 
countries.3,10 It is predicted that obesity-related syndromes 
can lead to decline in life expectancy.46 Obesity is considered 
a heritable neurobehavioral disorder that is highly sensitive 
to environmental conditions.47 Large-scale molecular 
approaches shall continue to identify genetic factors 
important in predisposition to obesity.11 Clinical significance 
of such associations needs further studies.
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